Inj ceftazidime per 500 mg
Products billed under this code include Ceftazidime, Tazicef.
Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J0713
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ceftazidime | Sagent Pharmaceuticals | 25021-0127-20 | 50 | $77.45 |
| Ceftazidime | Sagent Pharmaceuticals | 25021-0127-66 | 50 | $77.45 |
| Ceftazidime | Sagent Pharmaceuticals | 25021-0128-50 | 40 | $61.96 |
| Ceftazidime | Sagent Pharmaceuticals | 25021-0128-67 | 40 | $61.96 |
| Ceftazidime | Sagent Pharmaceuticals | 25021-0129-69 | 72 | $111.528 |
| Ceftazidime | Sagent Pharmaceuticals | 25021-0129-99 | 72 | $111.528 |
| Ceftazidime | WG Critical Care, LLC | 44567-0235-25 | 50 | $77.45 |
| Ceftazidime | WG Critical Care, LLC | 44567-0236-10 | 40 | $61.96 |
| Ceftazidime | WG Critical Care, LLC | 44567-0237-06 | 72 | $111.528 |
| Tazicef | Pfizer Inc | 00409-5082-10 | 20 | $30.98 |
Show all 15 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tazicef | Pfizer Inc | 00409-5082-16 | 50 | $77.45 |
| Tazicef | Pfizer Inc | 00409-5084-11 | 40 | $61.96 |
| Tazicef | Pfizer Inc | 00409-5086-11 | 120 | $185.88 |
| Tazicef | Pfizer Inc | 00409-5092-16 | 50 | $77.45 |
| Tazicef | Pfizer Inc | 00409-5093-11 | 40 | $61.96 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.549 | +$0.106 | 500 MG | Inj ceftazidime per 500 mg | v1, posted September 17, 2026 |
| 3Q26 | $1.443 | +$0.038 | 500 MG | Inj ceftazidime per 500 mg | v1, posted September 15, 2026 |
| 2Q26 | $1.405 | −$0.063 | 500 MG | Inj ceftazidime per 500 mg | v1, posted September 15, 2026 |
| 1Q26 | $1.468 | −$0.103 | 500 MG | Inj ceftazidime per 500 mg | v1, posted September 15, 2026 |
| 4Q25 | $1.571 | −$0.071 | 500 MG | Inj ceftazidime per 500 mg | v1, posted September 8, 2026 |
| 3Q25 | $1.642 | +$0.042 | 500 MG | Inj ceftazidime per 500 mg | v1, posted March 10, 2026 |
| 2Q25 | $1.60 | −$0.048 | 500 MG | Inj ceftazidime per 500 mg | v1, posted March 10, 2026 |
| 1Q25 | $1.648 | −$0.012 | 500 MG | Inj ceftazidime per 500 mg | v1, posted December 19, 2025 |
| 4Q24 | $1.66 | +$0.041 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 11, 2025 |
| 3Q24 | $1.619 | −$0.038 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 11, 2025 |
| 2Q24 | $1.657 | −$0.037 | 500 MG | Inj ceftazidime per 500 mg | v1, posted March 11, 2025 |
| 1Q24 | $1.694 | −$0.085 | 500 MG | Inj ceftazidime per 500 mg | v1, posted December 19, 2024 |
| 4Q23 | $1.779 | −$0.057 | 500 MG | Inj ceftazidime per 500 mg | v1, posted October 10, 2024 |
| 3Q23 | $1.836 | −$0.019 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 5, 2024 |
| 2Q23 | $1.855 | −$0.123 | 500 MG | Inj ceftazidime per 500 mg | v1, posted February 23, 2024 |
| 1Q23 | $1.978 | +$0.041 | 500 MG | Inj ceftazidime per 500 mg | v1, posted December 6, 2023 |
| 4Q22 | $1.937 | −$0.155 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 22, 2023 |
| 3Q22 | $2.092 | +$0.116 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 9, 2023 |
| 2Q22 | $1.976 | +$0.013 | 500 MG | Inj ceftazidime per 500 mg | v1, posted December 14, 2022 |
| 1Q22 | $1.963 | −$0.004 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 8, 2022 |
| 4Q21 | $1.967 | +$0.068 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 2, 2022 |
| 3Q21 | $1.899 | −$0.106 | 500 MG | Inj ceftazidime per 500 mg | v1, posted June 2, 2022 |
| 2Q21 | $2.005 | +$0.027 | 500 MG | Inj ceftazidime per 500 mg | v1, posted March 1, 2022 |
| 1Q21 | $1.978 | – | 500 MG | Inj ceftazidime per 500 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026
- 1Q25: 2025-12-19_january-2025-asp-pricing-file-03-11-25-final-file.zipposted December 19, 2025
- 4Q24: 2025-06-11_october-2024-asp-pricing-file.zipposted June 11, 2025
- 3Q24: 2025-06-11_july-2024-asp-pricing-file.zipposted June 11, 2025
- 2Q24: 2025-03-11_april-2024-asp-pricing-file.zipposted March 11, 2025
- 1Q24: 2024-12-19_january-2024-asp-pricing-file.zipposted December 19, 2024
- 4Q23: 2024-10-10_october-2023-asp-pricing-file.zipposted October 10, 2024
- 3Q23: 2024-06-05_july-2023-asp-pricing-file.zipposted June 5, 2024
- 2Q23: 2024-02-23_april-2023-asp-pricing-file.zipposted February 23, 2024
- 1Q23: 2023-12-06_january-2023-asp-pricing-file.zipposted December 6, 2023
- 4Q22: 2023-06-22_october-2022-asp-pricing-file.zipposted June 22, 2023
- 3Q22: 2023-06-09_july-2022-asp-pricing-file.zipposted June 9, 2023
- 2Q22: 2022-12-14_april-2022-asp-pricing-file.zipposted December 14, 2022
- 1Q22: 2022-06-08_january-2022-asp-pricing-file.zipposted June 8, 2022
- 4Q21: 2022-06-02_october-2021-asp-pricing-file.zipposted June 2, 2022
- 3Q21: 2022-06-02_july-2021-asp-pricing-file.zipposted June 2, 2022
- 2Q21: 2022-03-01_april-2021-asp-pricing-file.zipposted March 1, 2022
- 1Q21: 2021-12-10_january-2021-asp-pricing-file.zipposted December 10, 2021